Eva Vanessa S.
- Country
- Germany
- Department
- Nephrology and Medical Intensive Care
Research Overview
- Safety and Proof-of-Concept Study of Vonafexor in Patients with Alport Syndrome at Risk of Progression
- Evaluation of Safety and Efficacy of ABBV-CLS-628 in Adults with Autosomal Dominant Polycystic Kidney Disease: A Phase 2 Randomized, Double-blind, Placebo-controlled Study
- STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease
Data & Insights
Has run more than one trial at 13 of 53 partner sites.
Specializations
Kidney Disorders
The investigator specializes in treating complex renal conditions, with particular emphasis on Alport syndrome and its progression in different patient populations.
- Progressive renal conditions
- Early-stage kidney disease interventions
- Hereditary kidney disorders
Their work includes evaluation of novel therapeutic approaches for kidney disease management.
Genetic Kidney Diseases
Focused on treating Autosomal Dominant Polycystic Kidney Disease (ADPKD), exploring innovative therapeutic combinations to improve patient outcomes.
- Renal cyst formation
- Kidney function preservation
- Treatment tolerability optimization
Their research addresses both disease progression and quality of life considerations in genetic kidney conditions.
Novel Therapeutics
The investigator explores cutting-edge treatments including SGLT2 inhibitors and vasopressin receptor antagonists for various kidney conditions.
- Innovative drug combinations
- Renoprotective strategies
- Treatment optimization
Their work encompasses both established and experimental therapeutic approaches in nephrology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.